Drugs / HER-2 pulsed Dendritic Cell Vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02063724 | Oct 2014 → Sep 2017 | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT02061423 | Apr 2014 → Feb 2019 | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02061332 | Jul 2009 → Aug 2014 | ductal breast carcinoma in situ | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER-2 pulsed Dendritic Cell Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02063724 ↗ |
| Modality | Vaccine | “HER-2 pulsed dendritic cell vaccines” NCT02061332 ↗ |
| Route | Other | “will be injected into 1-2 different normal groin lymph nodes or axillary nodes” NCT02061423 ↗ |